Loading...
Loading...
COEPW| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 250.3K |
| Gross Profit | -250.3K |
| Operating Expense | 6,449.4K |
| Operating I/L | -6,449.4K |
| Other Income/Expense | -1,329.3K |
| Interest Income | 0.0K |
| Pretax | -7,868.2K |
| Income Tax Expense | 1,387.5K |
| Net Income/Loss | -9,255.7K |
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company specializing in the development and commercialization of generic and branded pharmaceutical products and cell therapy platforms for cancer patients. Their product portfolio includes CD38-GEAR-NK, a Vy-Gen drug product for treating CD38-related cancers such as multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia. Additionally, they offer CD38-Diagnostic, an in vitro screening tool to identify cancer patients who are likely to benefit from targeted anti-CD38 monoclonal antibody therapies. The company also collaborates with Statera BioPharma to develop STAT-201 for Crohn's disease and with Vici Health Sciences, LLC to co-develop CPT60621 for Parkinson's Disease treatment.
